自噬抑制与肿瘤

自噬是一种在正常细胞和病理状态细胞中普遍存在的生理机制。自噬与肿瘤细胞的生存与凋亡关系密切,在很多肿瘤细胞中,其自噬活性均有改变。抑制肿瘤细胞中自噬活动可以促进肿瘤细胞的凋亡。在化疗诱导肿瘤细胞凋亡的同时,以自噬抑制剂抑制肿瘤细胞的自噬活动,可改善肿瘤的治疗效果。     

细胞自噬在肿瘤化疗耐药中的作用

肿瘤有多种机制产生化疗药物耐药性．自噬是一种在正常细胞和病理细胞中普遍存在的生理机制,调控自噬的分子和信号传导通路错综复杂．自噬与凋亡有着独特的交叉联系,使得自噬在肿瘤化疗耐药性中发挥着促进或抑制耐药的双重作用．自噬在肿瘤耐药中的这种截然相反的作用与化疗给药浓度、细胞类型、自噬强度等因素有关,但具体机制尚未完全明确．然而,将自噬途径作为治疗肿瘤、降低化疗药物耐药性的靶点有着广阔的应用前景．     

肿瘤治疗过程中凋亡与自噬的关系

凋亡和自噬是参与维持机体正常的生理平衡和内环境稳定重要机制,与正常生长发育以及肿瘤等多种疾病发展过程都有着密切的联系。对于肿瘤的治疗,传统的方法是诱导肿瘤细胞凋亡,然而,肿瘤细胞中凋亡抗性的出现成为肿瘤治疗的主要障碍。近来,通过诱导其它细胞死亡方式致肿瘤细胞死亡已经成为有潜力的新的抗肿瘤机制。自噬作为另外一种细胞程序性死亡方式与凋亡一样有着复杂的分子机制和调控机制,它们之间存在密切的联系,并且存在许多相同的调节蛋白。本文就凋亡和自噬在形态特征、分子机制、检测方法以及在肿瘤治疗过程两者之间的关系做一综述。     

细胞自噬与肿瘤的关系研究进展

细胞自噬(autophagy)在肿瘤的发生发展过程中扮演着非常重要的角色。自噬作用是细胞的一种自我保护机制,是真核细胞用于清除细胞内聚物及受损细胞器,进而维持细胞内稳态的一种蛋白质降解途径。从细胞自噬的类型及其形成,细胞自噬的分子调控机制,自噬对肿瘤发生及发展、以及治疗耐药等恶性行为的影响,肿瘤中自噬与预后的关联,干预自噬对肿瘤治疗的影响和细胞自噬的研究方法等方面进行综述,以期为肿瘤的治疗提供新思路。     

p53与细胞死亡

p53是一种重要的肿瘤抑制因子,是迄今发现与人类肿瘤相关性最高的分子之一。超过50%的人类肿瘤含有p53基因突变。因此,p53是肿瘤治疗中的重要分子靶点。p53依赖的细胞凋亡是其抑制肿瘤的重要机制之一。然而,最近研究发现,p53不仅参与细胞凋亡,还与程序性细胞坏死、细胞自噬以及铁诱导的细胞死亡等细胞死亡途径相关。促使肿瘤细胞死亡是肿瘤治疗的重要目标。因此,进一步了解p53与细胞死亡之间的关系,将有助于探索以p53为靶点的肿瘤治疗和p53相关肿瘤细胞耐药机制。     

自噬与肿瘤耐受的关系

肿瘤是机体在各种致癌因素作用下,局部组织的某一个细胞在基因水平上失去对其生长的正常调控,导致其克隆性异常增生而形成的新生物。目前化疗和放疗是其治疗的重要手段,但一直以来,耐受性的产生成为肿瘤治疗的主要障碍。自噬是一种进化保守的溶酶体依赖的自身降解途径,越来越多的证据表明肿瘤的耐受性与自噬有关:放疗和化疗可以诱导保护性自噬的产生,帮助肿瘤细胞逃避凋亡途径。其机制可能与PI3KAkt-mTOR通路、Beclin 1、ATP、p53等有关,深入了解自噬与肿瘤耐受性之间的调控不仅为克服肿瘤细胞耐受性提供了靶点,也为自噬与凋亡关系的研究提供了线索。     

自噬与DNA损伤修复及其对肿瘤的影响

DNA损伤与肿瘤的发生发展密切相关。当DNA损伤发生时,会触发一系列的损伤应答反应以帮助细胞生存,其中即包括对自噬的诱导。ATM、P53和PARP1等多种参与DNA损伤修复的效应因子通过影响AMPK、mTOR以及一些凋亡蛋白等启动自噬。而作为一种降解途径,自噬则可通过调节DNA修复相关蛋白的水平直接影响同源重组修复、非同源末端连接修复和核苷酸切除修复等促进DNA修复,以及通过维持细胞内稳态间接促进DNA修复,从而在正常细胞的恶性转化和肿瘤耐药等发生机制中扮演重要角色。此外,DNA修复失败时,自噬也可作为一种肿瘤细胞的程序性死亡方式。因此研究自噬通过调节DNA损伤修复而对肿瘤的影响对于理解肿瘤发生的机制和提供治疗思路都有重要意义。     

细胞自噬研究进展

细胞自噬是真核生物在进化过程中高度保守、基于溶酶体的一种胞内降解途径,对维持细胞和生物体的稳态平衡有重要作用。研究表明,自噬参与生物体发育、免疫反应、代谢调节、细胞凋亡和衰老等多种过程。自噬功能异常与神经退行性疾病、肿瘤等的发生发展密切相关。近30年,我们对细胞自噬的认识无论是在分子机制上还是生理功能方面都有了长足的发展。为进一步加深对细胞自噬的认识,该文主要对细胞自噬的概念、自噬核心机器的组成及调控机制、自噬类型、生理功能及与疾病的关系作一简单综述。     

自噬的形态特征及分子调控

自噬过程是生物进化过程中保留下来的一种细胞蛋白和细胞器的循环利用机制,一般认为自噬过程对于细胞在恶劣环境下生存具有重要意义.而细胞的发育和凋亡与自噬有着密切的关系.本文通过自噬体的形成方式综述了三种自噬形式的形态特征以及自噬的分子调控对细胞的影响.     

综述: 细胞自噬在肿瘤发生发展中的作用

自噬是保守的细胞防御机制,又是程序性细胞死亡机制．在多种人类肿瘤中存在细胞自噬活性改变．自噬活性降低促进肿瘤的发生和进展．综述了近年来细胞自噬在肿瘤中的研究进展,从基因组不稳定性、炎-癌链转化和演进、致瘤微生 物感染和宿主免疫应答、细胞凋亡途径与自噬的交叉调节等角度探讨自噬抑制肿瘤的机理,以及细胞自噬在肿瘤治疗中的作用．     

Autophagy and tumorigenesis

Autophagy, or cellular self-digestion, is activated in cancer cells in response to multiple stresses and has been demonstrated to promote tumor cell survival and drug resistance. Nonetheless, genetic evidence supports that autophagy functions as a tumor suppressor mechanism. Hence, the precise role of autophagy during cancer progression and treatment is both tissue and context dependent. Here, we discuss our current understanding of the biological functions of autophagy during cancer development, overview how autophagy is regulated by cancer-associated signaling pathways, and review how autophagy inhibition is being exploited to improve clinical outcomes.     

Autophagy regulation and its role in normal and malignant hematopoiesis

Autophagy, the molecular machinery of self-eating, plays a dual role of a tumor promoter and tumor suppressor. This mechanism affects different clinical responses in cancer cells. Autophagy is targeted for treating patients resistant to chemotherapy or radiation. Limited reports investigate the significance of autophagy in cancer therapy, the regulation of hematopoietic and leukemic stem cells and leukemia formation. In the current review, the role of autophagy is discussed in various stages of hematopoiesis including quiescence, self-renewal, and differentiation.     

Role and regulation of autophagy in cancer

Autophagy is an intracellular self-degradative mechanism which responds to cellular conditions like stress or starvation and plays a key role in regulating cell metabolism, energy homeostasis, starvation adaptation, development and cell death. Numerous studies have stipulated the participation of autophagy in cancer, but the role of autophagy either as tumor suppressor or tumor promoter is not clearly understood. However, mechanisms by which autophagy promotes cancer involves a diverse range of modifications of autophagy associated proteins such as ATGs, Beclin-1, mTOR, p53, KRAS etc. and autophagy pathways like mTOR, PI3K, MAPK, EGFR, HIF and NFκB. Furthermore, several researches have highlighted a context-dependent, cell type and stage-dependent regulation of autophagy in cancer. Alongside this, the interaction between tumor cells and their microenvironment including hypoxia has a great potential in modulating autophagy response in favour to substantiate cancer cell metabolism, self-proliferation and metastasis. In this review article, we highlight the mechanism of autophagy and their contribution to cancer cell proliferation and development. In addition, we discuss about tumor microenvironment interaction and their consequence on selective autophagy pathways and the involvement of autophagy in various tumor types and their therapeutic interventions concentrated on exploiting autophagy as a potential target to improve cancer therapy.     

Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis

Autophagy and apoptosis are 2 fundamental biological mechanisms that may cooperate or be antagonistic, although both are involved in deciding the fate of cells in physiological or pathological conditions. These 2 mechanisms coexist simultaneously in cells and share common upstream signals and stimuli. Autophagy and apoptosis play pivotal roles in cancer development. Autophagy plays a key function in maintaining tumor cell survival by providing energy during unfavorable metabolic conditions through its recycling mechanism, and supporting the high energy requirement for metabolism and growth. This review focuses on gastrointestinal stromal tumors and cell death through autophagy and apoptosis, taking into account the involvement of both of these processes in tumor development and growth and as mechanisms of drug resistance. We also focus on the crosstalk between autophagy and apoptosis as an emerging field with major implications for the development of novel therapeutic options.     

Autophagy: a barrier or an adaptive response to cancer

Macroautophagy or autophagy is a degradative pathway terminating in the lysosomal compartment after the formation of a cytoplasmic vacuole that engulfs macromolecules and organelles. The recent discovery of the molecular controls of autophagy that are common to eukaryotic cells from yeast to human suggests that the role of autophagy in cell functioning is far beyond its nonselective degradative capacity. The involvement of proteins with properties of tumor suppressor and oncogenic properties at different steps of the pathway implies that autophagy must be considered in tumor progression. Autophagy as a stress response mechanism protects cancer cells from low nutrient supply or therapeutic insults. Autophagy is also involved in the elimination of cancer cells by triggering a non-apoptotic cell death program, suggesting a negative role in tumor development. These two aspects of autophagy will be discussed in this review.     

Autophagy and cancer

Autophagy is a homeostatic and evolutionarily conserved mechanism of self-digestion by which the cells degrade and recycle long-lived proteins and excess or damaged organelles.Autophagy is activated in response to both physiological and pathological stimuli including growth factor depletion,energy deficiency or the upregulation of Bcl-2 protein expression.A novel role of autophagy in various cancers has been proposed.Interestingly,evidence that supports both a positive and negative role of autophagy in the pathogenesis of cancer has been reported.As a tumor suppression mechanism,autophagy maintains genome stability,induces senescence and possibly autophagic cell death.On the other hand,autophagy participates in tumor growth and maintenance by supplying metabolic substrate,limiting oxidative stress,and maintaining cancer stem cell population.It has been proposed that the differential roles of autophagy in cancer are disease type and stage specific.In addition,substrate selectivity might be involved in carrying out the specific effect of autophagy in cancer,and represents one of the potential directions for future studies.     

内质网应激与自噬及其交互作用影响内皮细胞凋亡

内质网应激是普遍存在于真核细胞中的应激-防御机制。在内环境稳态遭到破坏的情况下,未折叠蛋白质反应的3条信号通路,分别通过增强蛋白质折叠能力、减少蛋白质生成和促进内质网相关蛋白质降解等途径缓解细胞内压力。同时,也通过多种分子信号机制调控细胞凋亡。自噬是一种生理性的降解机制。通过形成自噬泡并与溶酶体结合摄取并水解胞内受损细胞器和蛋白质等,清除代谢废物,维持细胞正常功能。自噬缺陷或过度激活均可导致细胞凋亡或非程序性死亡。自噬的程度和细胞内压力水平有关。内质网应激通过未折叠蛋白质反应和Ca²⁺浓度变化及其相关分子信号调控自噬。自噬又可反馈性调节内质网应激反应,二者相互作用,在内皮细胞凋亡过程中发挥重要作用。未来内质网应激和自噬可作为药物靶点为内皮相关性疾病提供诊疗策略。     

Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma

Autophagy is a catabolic process critical to maintaining cellular homeostasis and responding to cytotoxic insult. Autophagy is recognized as “programmed cell survival” in contrast to apoptosis or programmed cell death. Upregulation of autophagy has been observed in many types of cancers and has been demonstrated to both promote and inhibit antitumor drug resistance depending to a large extent on the nature and duration of the treatment-induced metabolic stress as well as the tumor type. Cisplatin, doxorubicin and methotrexate are commonly used anticancer drugs in osteosarcoma, the most common form of childhood and adolescent cancer. Our recent study demonstrated that high mobility group box 1 protein (HMGB1)-mediated autophagy is a significant contributor to drug resistance in osteosarcoma cells. Inhibition of both HMGB1 and autophagy increase the drug sensitivity of osteosarcoma cells in vivo and in vitro. Furthermore, we demonstrated that the ULK1-FIP200 complex is required for the interaction between HMGB1 and BECN1, which then promotes BECN1-PtdIns3KC3 complex formation during autophagy. Thus, these findings provide a novel mechanism of osteosarcoma resistance to therapy facilitated by HMGB1-mediated autophagy and provide a new target for the control of drug-resistant osteosarcoma patients.     

Extracellular matrix regulation of autophagy

Integrin-mediated attachment of epithelial cells to extracellular matrix (ECM) is crucial for proper growth and survival. Although detachment leads to apoptosis, termed anoikis, recent work demonstrates that ECM detachment also robustly induces autophagy, a tightly regulated lysosomal self-digestion process that actually promotes survival. Autophagy presumably protects epithelial cells from the stresses of ECM detachment, allowing them to survive provided that they reattach in a timely manner. Currently, the intracellular signals linking integrin engagement to autophagy remain unclear, but certain growth factor, energy-sensing, and stress-response pathways represent attractive candidates. Moreover, autophagy may be a previously unrecognized mechanism utilized by detached cancer cells to survive anoikis, which may facilitate tumor cell dormancy, dissemination, and metastasis.     

Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma

Autophagy is a catabolic process critical to maintaining cellular homeostasis and responding to cytotoxic insult. Autophagy is recognized as "programmed cell survival" in contrast to apoptosis or programmed cell death. Upregulation of autophagy has been observed in many types of cancers and has been demonstrated to both promote and inhibit antitumor drug resistance depending to a large extent on the nature and duration of the treatment-induced metabolic stress as well as the tumor type. Cisplatin, doxorubicin and methotrexate are commonly used anticancer drugs in osteosarcoma, the most common form of childhood and adolescent cancer. Our recent study demonstrated that high mobility group box 1 protein (HMGB1)-mediated autophagy is a significant contributor to drug resistance in osteosarcoma cells. Inhibition of both HMGB1 and autophagy increase the drug sensitivity of osteosarcoma cells in vivo and in vitro. Furthermore, we demonstrated that the ULK1-FIP200 complex is required for the interaction between HMGB1 and BECN1, which then promotes BECN1-PtdIns3KC3 complex formation during autophagy. Thus, these findings provide a novel mechanism of osteosarcoma resistance to therapy facilitated by HMGB1-mediated autophagy and provide a new target for the control of drug-resistant osteosarcoma patients.